Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.

Autor: Pal, Sumanta Kumar, Grivas, Petros, Gupta, Shilpa, Valderrama, Begoña Pérez, Rodriguez-Vida, Alejo, Roghmann, Florian, Sevillano, Elena, Matin, Surena F., Loriot, Yohann, Sridhar, Srikala S., Sonpavde, Guru P., Fleming, Mark T., Lerner, Seth P., Bellmunt, Joaquim, Master, Viraj A., Tripathi, Abhishek, Davis, Kim, Van Veenhuyzen, David Friedrich, Weng, Richard, Daneshmand, Siamak
Zdroj: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p629-629, 193p
Databáze: Supplemental Index